menu
    • menu
    [{"orgOrder":0,"company":"Aurinia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"AUR200","moa":"BAFF\/APRIL","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Aurinia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aurinia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Aurinia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"SC291","moa":"CD19","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sana Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Sana Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Concept Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Concept Medical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Concept Medical \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Concept Medical \/ Undisclosed"},{"orgOrder":0,"company":"Saniona","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SAN903","moa":"KCa3.1","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saniona \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Saniona \/ Undisclosed"},{"orgOrder":0,"company":"Saniona","sponsor":"University of Arhus","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SAN903","moa":"KCa3.1","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saniona \/ University of Arhus","highestDevelopmentStatusID":"5","companyTruncated":"Saniona \/ University of Arhus"},{"orgOrder":0,"company":"Alebund Pharmaceuticals","sponsor":"3H Health Investment","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Series B Financing","leadProduct":"AP-302","moa":"MASP-2","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Alebund Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Alebund Pharmaceuticals \/ 3H Health Investment","highestDevelopmentStatusID":"5","companyTruncated":"Alebund Pharmaceuticals \/ 3H Health Investment"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"TST004","moa":"MASP-2","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Transcenta Holding \/ Undisclosed"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"TST004","moa":"MASP-2","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Transcenta Holding \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Transcenta Holding \/ Undisclosed"},{"orgOrder":0,"company":"Ventus Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VENT-01","moa":"NLRP3","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Ventus Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ventus Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"5","companyTruncated":"Ventus Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Federation Bio","sponsor":"Horizons Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Series A Financing","leadProduct":"Human Gut Microbiome","moa":"Undisclosed","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Federation Bio","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Federation Bio \/ Horizons Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Federation Bio \/ Horizons Ventures"},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Jade Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Merger","leadProduct":"JADE-001","moa":"Undisclosed","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Aerovate Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aerovate Therapeutics \/ Jade Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Aerovate Therapeutics \/ Jade Biosciences"},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Jade Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Merger","leadProduct":"JADE-001","moa":"Undisclosed","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Aerovate Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aerovate Therapeutics \/ Jade Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Aerovate Therapeutics \/ Jade Biosciences"},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Jade Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Merger","leadProduct":"JADE-001","moa":"Undisclosed","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Aerovate Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aerovate Therapeutics \/ Jade Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Aerovate Therapeutics \/ Jade Biosciences"},{"orgOrder":0,"company":"Delta Crystallon","sponsor":"Serenity Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Protein","year":"2022","type":"Acquisition","leadProduct":"Recombinant Human HspB5","moa":"Undisclosed","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Delta Crystallon","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delta Crystallon \/ Serenity Bioworks","highestDevelopmentStatusID":"5","companyTruncated":"Delta Crystallon \/ Serenity Bioworks"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MTX652","moa":"USP-30","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Mission Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mission Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Mission Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"MTX652","moa":"USP-30","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Mission Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mission Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Mission Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Opterion Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"OPT101","moa":"Undisclosed","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Opterion Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Opterion Health \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Opterion Health \/ Undisclosed"},{"orgOrder":0,"company":"eGenesis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"EGEN-2784","moa":"Undisclosed","graph1":"Nephrology","graph2":"IND Enabling","graph3":"eGenesis","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"eGenesis \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"eGenesis \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Opterion Health

                            Switzerland arrow
                            OTS 2025
                            Not Confirmed

                            Opterion Health

                            Switzerland arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OPT101

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Opterion Health Seeks Approval for First-in-Human OPT101 Study in Advanced CKD

                            Details : OPT101 is a novel non-glucose-based osmotic agent bringing much-needed new therapy options to patients with renal failure.

                            Product Name : OPT101

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 17, 2025

                            Lead Product(s) : OPT101

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            eGenesis

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            eGenesis

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EGEN-2784

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            eGenesis Gets IND Clearance for EGEN-2784 in Kidney Transplant Study

                            Details : EGEN-2784 is a genetically engineered porcine-derived kidney, in patients with end stage kidney disease (ESKD).

                            Product Name : EGEN-2784

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 08, 2025

                            Lead Product(s) : EGEN-2784

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aerovate Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Aerovate Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JADE-001

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : Jade Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Jade Merges with Aerovate, Secures $300M in Private Placement Funding

                            Details : The combined company will focus on advancing Jade’s portfolio of novel biologics, including JADE-001, a promising anti-APRIL monoclonal antibody for IgA nephropathy.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 28, 2025

                            Lead Product(s) : JADE-001

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : Jade Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Purespring Therapeutics

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed

                            Purespring Therapeutics

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PS-002

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Purespring Wins EMA Orphan Drug Status for PS-002 in IgA Nephropathy

                            Details : PS-002 is a Purespring’s lead cell and gene therapy programme, currently being investigated in patients with IgA nephropathy (IgAN).

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 28, 2025

                            Lead Product(s) : PS-002

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Purespring Therapeutics

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed

                            Purespring Therapeutics

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PS-002

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : Sofinnova Partners

                            Deal Size : $105.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Purespring Therapeutics Raises $105M to Transform Kidney Disease Treatment

                            Details : The proceeds will be used to support Purespring’s pipeline including the initiation of a Phase I/II clinical trial of PS-002 for IgAN, a chronic kidney disease primarily affecting young adults.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            October 09, 2024

                            Lead Product(s) : PS-002

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : Sofinnova Partners

                            Deal Size : $105.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Concept Medical

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Concept Medical

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Concept Medical Receives FDA IDE Approval for Magictouch AVF Indication

                            Details : FDA approved MagicTouch AVF, a Sirolimus drug-coated balloon catheter, for clinical trials treating stenotic lesions of Arteriovenous Fistula in patients with chronic renal failure.

                            Product Name : MagicTouch AVF

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            April 02, 2024

                            Lead Product(s) : Sirolimus

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Atara Biotherapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Atara Biotherapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATA3219

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Atara Biotherapeutics Receives FDA IND Clearance for ATA3219 in Lupus Nephritis

                            Details : ATA3219 is an allogeneic, anti-CD19 chimeric antigen receptor (CAR) T-cell monotherapy, e=which is being evaluated for the treatment of Lupus Nephritis.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            February 29, 2024

                            Lead Product(s) : ATA3219

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Aurinia Pharmaceuticals

                            Canada arrow
                            OTS 2025
                            Not Confirmed

                            Aurinia Pharmaceuticals

                            Canada arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AUR200

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aurinia Submits IND Application to US Food & Drug Administration for AUR 200

                            Details : AUR200s a highly potent and specific Fc-fusion protein, which is a BAFF/APRIL inhibitor. Currently, it is being evaluated in the IND enabling studies for the treatment of autoimmune diseases such as IgA nephropathy and systemic lupus erythematosus.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 20, 2023

                            Lead Product(s) : AUR200

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Mission Therapeutics

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed

                            Mission Therapeutics

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MTX652

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mission Therapeutics Announces US FDA Approval to Initiate Phase II Clinical Trial of its Lead Asset MTX652 in...

                            Details : MTX652 is a potent and selective compound designed to improve mitochondrial quality and function by enhancing mitophagy through inhibition of USP30 enzyme. It is being evaluated for the treatment of acute kidney injury (AKI) following cardiac surgery.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 14, 2023

                            Lead Product(s) : MTX652

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Everest Medicines

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Everest Medicines

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zetomipzomib

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Everest Medicines Announces Investigational New Drug Application Acceptance of Zetomipzomib in China

                            Details : KZR-616 (zetomipzomib) is a novel, first-in-class, selective immunoproteasome inhibitor. It is currently being evaluated for the treatment of Lupus Nephritis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 03, 2023

                            Lead Product(s) : Zetomipzomib

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth